SCHEMBL3488477

SCHEMBL3488477

CN1CCN(c2cc(Cl)cc3c2S(=O)(=O)N(Cc2cccc([N+](=O)[O-])c2)C(=O)N3Cc2ccccc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.45
CA9 Q16790 2/20 0.45
CA2 P00918 1/20 0.45
ALDH1A1 P00352 5/20 0.43
LMNA P02545 3/20 0.43
KDM4E B2RXH2 2/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.41
BCL2A1 Q16548 1/20 0.41
HTR1A P08908 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3489541 0.93 RAB9A (0.42) CA12CA9ALDH1A1LMNAKDM4E
SCHEMBL3490278 0.89 MAPT (0.48) ALDH1A1LMNAKDM4EMAPTMAPK1
SCHEMBL3490480 0.88 MAPT (0.47) ALDH1A1LMNAKDM4EMAPTMAPK1
SCHEMBL3489318 0.86 MAPT (0.45) CA12CA9ALDH1A1LMNAKDM4E
SCHEMBL3490199 0.86 CA12 (0.50) CA12CA9CA2ALDH1A1LMNA
SCHEMBL3489623 0.86 MAPT (0.46) CA12CA9ALDH1A1LMNAKDM4E
SCHEMBL3491688 0.86 CA12 (0.40) CA12CA9CA2LMNAKDM4E
SCHEMBL3490153 0.86 CMA1 (0.46) ALDH1A1LMNAKDM4EPOLBMAPT
SCHEMBL3489163 0.85 MAPT (0.43) CA12CA9CA2LMNAKDM4E
SCHEMBL3490669 0.85 MAPT (0.42) CA12CA9CA2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US claimed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D CA12 4883/4885CA9 4884/4885CA2 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.